SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 57 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,151,000 | +79.0% | 123,683 | +0.9% | 0.00% | +50.0% |
| Q1 2019 | $643,000 | +18.0% | 122,553 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $545,000 | -46.7% | 122,553 | -3.2% | 0.00% | -33.3% |
| Q3 2018 | $1,023,000 | +15.1% | 126,663 | 0.0% | 0.00% | +50.0% |
| Q2 2018 | $889,000 | -51.3% | 126,663 | -1.2% | 0.00% | -60.0% |
| Q1 2018 | $1,824,000 | +65.4% | 128,198 | +1.8% | 0.01% | +66.7% |
| Q4 2017 | $1,103,000 | -15.8% | 125,887 | +12.5% | 0.00% | -25.0% |
| Q3 2017 | $1,310,000 | -14.1% | 111,923 | +2.5% | 0.00% | -20.0% |
| Q2 2017 | $1,525,000 | +7.3% | 109,168 | +5.4% | 0.01% | +25.0% |
| Q1 2017 | $1,421,000 | +84.1% | 103,540 | -3.8% | 0.00% | +33.3% |
| Q4 2016 | $772,000 | -42.9% | 107,680 | +20.7% | 0.00% | -40.0% |
| Q3 2016 | $1,352,000 | +143.2% | 89,200 | +58.2% | 0.01% | +150.0% |
| Q2 2016 | $556,000 | -28.0% | 56,400 | -2.7% | 0.00% | -33.3% |
| Q1 2016 | $772,000 | – | 57,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |